Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ags Therapeutics SAS focuses its patenting efforts in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This prosecution activity involves 1 distinct examiner and is located within 1 distinct art unit. Such a focused profile indicates that the company's current patent office interactions are limited to a single application or a very narrow set of claims. Practitioners can dedicate their efforts to understanding the specific nuances of this 1 distinct art unit to optimize their response strategy.
ALAM, AYAAN A is the busiest examiner for this portfolio, currently overseeing 1 pending office action. This 1 pending office action represents the entirety of the company's active office action volume, meaning all current prosecution attention is directed toward this individual examiner. With only 1 distinct examiner involved, the company has a clear and singular point of contact for its current pending matters. This concentration simplifies the management of the portfolio, as there is only 1 pending office action to track and only the style of Examiner ALAM, AYAAN A to consider during the prosecution process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, AYAAN A | 1 | 38.4% | +35.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18417747 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR PREPARATION, AND USES | ALAM, AYAAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18417747 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR PREPARATION, AND USES | ALAM, AYAAN A | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18417747 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR PREPARATION, AND USES | ALAM, AYAAN A | 1611 | §101§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial